The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...

BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major ...